 |
||
|
Integrated Risk Information System |  |
 |
||
|
|
|
|
|||||||||
|
Vinyl chloride (CASRN 75-01-4)
Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development. Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the Full IRIS Summary to put this information into complete context. For definitions of terms in the IRIS Web site, refer to the IRIS Glossary. Status of Data for Vinyl chlorideFile First On-Line: 08/07/2000 Last Significant Revision: 08/07/2000
|
| Critical Effect | Experimental Dose | |||
|---|---|---|---|---|
| Liver cell polymorphism | NOAEL (HED): 0.09 mg/kg-day | 30 |
1 |
3 x10-3 mg/kg-day |
The Experimental Dose listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.
| Critical Effect | Experimental Dose | |||
|---|---|---|---|---|
| Liver cell polymorphism | NOAEL (HEC): 2.5 mg/m3 | 30 |
1 |
1x10-1 mg/m3 |
The Experimental Dose listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.
Weight of Evidence Narrative:
Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that VC is a known human carcinogen by the inhalation route of exposure, based on human epidemiological data, and by analogy the oral route because of positive animal bioassay data as well as pharmacokinetic data allowing dose extrapolation across routes. VC is also considered highly likely to be carcinogenic by the dermal route because it is well absorbed and acts systemically.
This may be a synopsis of the full weight-of-evidence narrative. See Full IRIS Summary.
| Oral Slope Factor(s) | Extrapolation Method |
|---|---|
|
7.2x10-1 per mg/kg-day 1 (Continuous lifetime exposure during adulthood) |
LMS method |
|
1.5 per mg/kg-day 1 (Continuous lifetime exposure from birth) |
LED 10/ linear method |
1 This represents the lowest/highest of multiple discrete slope factors for this substance. See Full IRIS Summary.
Drinking Water Unit Risk(s)
2.1x10-2 per mg/L 1
(Continuous lifetime exposure during adulthood)
4.2x10-2 per mg/L 1
(Continuous lifetime exposure from birth)
1 This represents the lowest/highest of drinking water unit risks for this substance. See Full IRIS Summary.
| Risk Level | Concentration |
|---|---|
| E-4 (1 in 10,000) | 2.4x10-3 mg/L(Continuous lifetime exposure from birth) |
| E-5 (1 in 100,000) | 2.4x10-4 mg/L(Continuous lifetime exposure from birth) |
| E-6 (1 in 1,000,000) | 2.4x10-5 mg/L(Continuous lifetime exposure from birth) |
| E-4 (1 in 10,000) | 4.8x10-3 mg/L(Continuous lifetime exposure during adulthood) |
| E-5 (1 in 100,000) | 4.8x10-4 mg/L(Continuous lifetime exposure during adulthood) |
| E-6 (1 in 1,000,000) | 4.8x10-5 mg/L(Continuous lifetime exposure during adulthood) |
Dose-Response Data (Carcinogenicity, Oral Exposure)
Tumor Type: Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules
Test Species: Female Wistar rats
Route: Oral, Diet
Reference: Feron et al., 1981
| Air Unit Risk(s) | Extrapolation Method |
|---|---|
| 4.4x10-3 per mg/m3 (Continuous lifetime exposure during adulthood) |
LMS method |
| 4.4x10-3 per mg/m3 (Continuous lifetime exposure during adulthood) |
LED 10/ linear method |
| 8.8x10-3 per mg/m3 (Continuous lifetime exposure from birth) |
LMS method |
| 8.8x10-3 per mg/m3 (Continuous lifetime exposure from birth) |
LED 10/ linear method |
| Risk Level | Concentration |
|---|---|
| E-4 (1 in 10,000) | 2.3x10-2 mg/m3(Continuous lifetime exposure during adulthood) |
| E-5 (1 in 100,000) | 2.3x10-3 mg/m3(Continuous lifetime exposure during adulthood) |
| E-6 (1 in 1,000,000) | 2.3x10-4 mg/m3(Continuous lifetime exposure during adulthood) |
Dose-Response Data (Carcinogenicity, Inhalation Exposure)
Tumor Type: Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules
Test Species: Female Sprague-Dawley rats
Route: Inhalation
Reference: Maltoni et al. (1981, 1984)
|
|
|
|
|
|
